1 / 24

Tumaini (CRT) Inc. Efficacy of a New Slow Release Mosquito Larvicide containing Novaluron

Tumaini (CRT) Inc. Efficacy of a New Slow Release Mosquito Larvicide containing Novaluron. AMCA 2012. SLOW RELEASE MOSQUITO LARVICIDE Details. Larvicide contains the active ingredient novaluron and utilizes novel formulation technology which has been patented in numerous countries

derora
Download Presentation

Tumaini (CRT) Inc. Efficacy of a New Slow Release Mosquito Larvicide containing Novaluron

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tumaini (CRT) Inc. Efficacy of a New Slow Release Mosquito Larvicide containing Novaluron AMCA 2012

  2. SLOW RELEASE MOSQUITO LARVICIDE Details • Larvicide contains the active ingredient novaluron and utilizes novel formulation technology which has been patented in numerous countries • Formulation controls rate of release of novaluron into water column • increases solubility of novaluron in water from 3 ppb to 10-15 ppb • Formulation also promotes dispersion of novaluron throughout the water column • products will be available in several different sizes and shapes to address different market needs • all products have same recipe and ai 1.2g/kg novaluron • Tradename for larvicide products are: Mosquiron 0.12P and Mosquiron 0.12CRD

  3. Mosquiron Product Details Mosquiron 0.12P pastilles (2 sizes) • Mosquiron 0.12CRD • controlled release device

  4. Mosquiron Product Details

  5. Mosquiron 2010 Field Trials PURPOSE: • Assess efficacy and duration of Mosquiron products when used under simulated field conditions and in different regions of the US and Canada

  6. Mosquiron 2010 Field Trials Experimental Design • Needed to take into consideration the mode of action of novaluron • Novaluron is a chitin synthesis inhibitor and effects can be cumulative; larvae can appear healthy and mortality may not be observed until adults emerge from pupal case • At high concentrations of novaluron (>5 ppb) effect on larvae can be rapid – 24 hours • Mortality can still occur at pupaleclosion caused by incomplete separation from pupal case – adult drowning Field Trial Locations • Canada – Portage la Prairie MB, Abbotsford BC • US – MarshallWI, Meansville GA, Panama City FL

  7. Mosquiron 2010 Field Trials Experimental Design

  8. Mosquiron 2010 Field Trials

  9. Mosquiron 2010 Field Trials Experimental Design • Eggs were introduced to treatment tanks approx . every 2 weeks • Culex eggrafts were placed directly on water surface at WI, MB, BC and FL sites • Once hatching occurred all trts. received a larval liquid food slurry • Food slurry was a standard formula consisting of liver powder/brewer’s yeast • Food administered 3-4 times/wk. until water was cloudy in appearance

  10. Mosquiron 2010 Field Trials Marshall - WI site Meansville - GA site

  11. Mosquiron 2010 Field Trials Panama City -FL Site

  12. Mosquiron 2010 Field Trials Portage la Prairie - MB Site

  13. Mosquiron 2010 Field Trials Abbotsford - BC Site

  14. Mosquiron 2010 Field Trials Data Collection • Treatments were inspected for the presence of live larvae and/or pupae on an as needed basis. Once 3rd and/or 4th instars were present, dips were taken to harvest live larvae. • Florida A&M’s PHEREC Standard Mosquito Sampling Method was used at all trial sites. • Using a standard mosquito dipper, eight dips were taken per treatment. • The number of larvae and/or pupae per dip were counted and recorded. Larvae were returned to the treatment tanks. • Once pupae were found, they were transferred to emergence jars for monitoring. • Adults that emerged successfully from pupal cases were counted and recorded as successful hatches. Dead adult mosquitoes on the water surface recorded as unsuccessful emergence.

  15. 2010 Field Trial Results BC location started 14-Jul-10

  16. 2010 Field Trial ResultsMB location started 7-Jul-10

  17. 2010 Field Trial ResultsWI location started 19-Jun-10

  18. 2010 Field Trial ResultsGA location started 2-Jul-10

  19. 2010 Field Trial ResultsFL location started 11-Jun-10

  20. 2010 Field Trial Observations • Using local sources for harvesting Culex eggrafts delayed start of trial in Northerly sites to early July • Was exacerbated by a cool wet spring in Canada and WI • FL location received very high precipitation (18” rain in July) causing significant dilution of novaluron in cement troughs Conclusions • Study results demonstrate Mosquiron formulations provided 100% IE for duration of study at all locations • 100% IE observed at FL site with 2x CRD

  21. Registration Status • Data packages to support 2 product labels (Mosquiron 0.12P and Mosquiron 0.12 CRD) submitted to EPA and PMRA • Anticipate label approvals from EPA in May, 2012 • PMRA approval later in the year

  22. Product Research - 2011 ELISA Method • Detection and quantification of novaluron in water at concentrations < 0.5 ppb in development Mesocosm Study • Study is still ongoing, completion spring 2012 U of Guelph • Bioassays conducted in water extracted from ponds treated at label rate demonstrate 100% IE after 120 days Further Information • For more information visit Tumaini booth in the Exhibit Hall • Poster Presentation on Mosquiron Mesocosm Study, Paddy McManus, U of Guelph

  23. Acknowledgements MakhteshimAgan North America (MANA) Dr. Rob Everich, MANA Dr. Chris Hall, U of Guelph Paddy McManus, U of Guelph Ken Michelson, International Ag Research Florida A&MPHEREC lab, Dr. Jack Peterson, Ken Shafer

More Related